{"id":"W2586804150","doi":"10.1200/jco.2006.24.18_suppl.3506","title":"A randomized trial of first-line irinotecan/fluoropymidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"ca_institutions":"Lakeridge Health","funders":"","keywords":"Medicine; Irinotecan; Capecitabine; Clinical endpoint; Bevacizumab; FOLFIRI; Celecoxib; Nausea; Placebo; Gastroenterology; Internal medicine; Bolus (digestion); Colorectal cancer; Tolerability; Vomiting; Randomized controlled trial; Chemotherapy; Adverse effect; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002407218,0.0002019747,0.003985707,0.0002294305,0.00004616688,0.000005760177,0.0001047731,0.0001533035,0.0002130563],"category_scores_gemma":[0.002395501,0.0001052833,0.0005177875,0.0003543854,0.0004970595,0.00007450872,0.00003414245,0.0005478209,0.000001188959],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003048559,"about_ca_system_score_gemma":0.001883856,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001274181,"about_ca_topic_score_gemma":0.02055097,"domain_scores_codex":[0.9956499,0.0005046786,0.002983876,0.0001935031,0.0004278207,0.0002401705],"domain_scores_gemma":[0.9927977,0.00418057,0.002114054,0.000110744,0.0006532082,0.00014377],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9506419,0.01034089,0.02565956,0.00004792569,0.00113039,0.0004008084,0.0001109631,0.0001034967,0.000017172,0.00008526757,0.000457462,0.01100412],"study_design_scores_gemma":[0.9187906,0.05330685,0.02185442,0.0001874002,0.001752799,0.0001379857,0.000080108,0.0004370644,0.0001469264,0.0003286015,0.002869712,0.0001075832],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9885226,0.0008842142,0.0001118897,0.006181015,0.0006306723,0.001368524,0.00001090672,0.00000803248,0.002282177],"genre_scores_gemma":[0.9950019,0.001598466,0.002038526,0.0001873377,0.0004739718,0.0001339711,0.000003817403,0.00001859505,0.0005434454],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04296596,"threshold_uncertainty_score":0.9973214,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1089623824251588,"score_gpt":0.4604463677779143,"score_spread":0.3514839853527555,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}